In recent years, brain diseases have seriously threatened human health due to their high morbidity and mortality. Achieving efficient drug delivery to provide satisfactory therapeutic outcomes is currently the greatest challenge in treating brain diseases. The main challenges are the structural peculiarities of the brain and the inability to transport drugs across the blood-brain barrier. Biomimetic nanodelivery systems (BNDSs) applied to the brain have been extensively developed in the preclinical phase to surmount these challenges. Considering the inherent properties of BNDSs, the substantially enhanced ability of BNDS to carry therapeutic agents and their higher selectivity toward lesions offer new opportunities for developing safe and effective therapies. This review summarizes brain-targeting nanotherapies, particularly advanced therapies with biomimetic nano-assistance. Prospects for developing BNDSs and the challenges of their clinical translation are discussed. Understanding and implementing biomimetic nanotherapies may facilitate the development of new targeted strategies for brain disorders.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jconrel.2023.05.009 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Modulation of β secretase and neuroinflammation by biomimetic nanodelivery system for Alzheimer's disease therapy.
J Control Release
December 2024
Key Laboratory of Environmental Medicine Engineering of Ministry of Education, State Key Laboratory of Bioelectronics, Jiangsu Engineering Laboratory of Smart Carbon-Rich Materials and Device, School of Public Health, School of Chemistry and Chemical Engineering, Southeast University, Nanjing 210009, PR China. Electronic address:
Alzheimer's disease (AD) is an irreversible and progressive neurodegenerative disorder. The vicious circle between amyloid-β peptide (Aβ) overgeneration and microglial dysfunction is an important pathological event that promotes AD progression. However, therapeutic strategies toward only Aβ or microglial modulation still have many problems.
View Article and Find Full Text PDFA Smart Nanomedicine Unleashes a Dual Assault of Glucose Starvation and Cuproptosis to Supercharge αPD-L1 Therapy.
Adv Sci (Weinh)
December 2024
Department of Respiratory and Critical Care Medicine, Center for Oncology Medicine, The Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu, 322000, China.
Combination therapy has become a promising strategy for promoting the outcomes of anti-programmed death ligand-1 (αPD-L1) therapy in lung cancer. Among all, emerging strategies targeting cancer metabolism have shown great potency in treating cancers with immunotherapy. Here, alteration in glucose and copper metabolisms is found to synergistically regulate PD-L1 expression in lung cancer cells.
View Article and Find Full Text PDFT Lymphocyte-Macrophage Hybrid Membrane-Coated Biomimetic Nanoparticles Alleviate Myocarditis via Suppressing Pyroptosis by Targeting Gene Silencing.
Int J Nanomedicine
December 2024
Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China.
Article Synopsis
- Nanomedicine using cell membrane coatings has gained interest due to improved targeting and reduced side effects, particularly focusing on treating myocarditis through IRF1-mediated macrophage pyroptosis.
- Researchers created a zeolitic imidazolate framework-8 (ZIF-8) nano-delivery system encapsulating siRNA aimed at IRF1, which was coated with a hybrid membrane from T lymphocytes and macrophages for efficient targeting.
- Findings indicated that the developed nanoparticles effectively delivered siRNA, reduced IRF1 expression, and decreased pyroptosis in macrophages, leading to a significant reduction in myocarditis progression in mice with minimal adverse effects.
Recent advances in biomimetic nanodelivery systems for the treatment of myocardial ischemia reperfusion injury.
Colloids Surf B Biointerfaces
November 2024
General Hospital of Northern Theater Command, Liaoning 110016, China. Electronic address:
Article Synopsis
- Myocardial ischemia/reperfusion injury (MIRI) is a major problem in treating heart attacks, which lead to serious heart damage and high mortality rates worldwide.
- The review explores the biological mechanisms behind MIRI and highlights new developments in biomimetic nanodelivery systems, such as cell membrane-coated nanoparticles, exosomes, and nanoenzymes, as potential treatments.
- The authors discuss the benefits and challenges of these innovative strategies, focusing on their effectiveness in lab studies and the hurdles to implementing them in real-world clinical settings.
Biomimetic mesenchymal stem cell membrane-coated nanoparticle delivery of MKP5 inhibits hepatic fibrosis through the IRE/XBP1 pathway.
J Nanobiotechnology
November 2024
School of Pharmaceutical Sciences, Jilin University, 1266 Fujin Road, Changchun, 130021, Jilin, China.
Article Synopsis
- Hepatic fibrosis is a serious disease with high rates of illness and death, but its mechanisms are not well understood, making treatment development difficult.
- The study found that lower levels of MKP5 in liver tissues from mice with fibrosis lead to more severe disease and suggested that MKP5 operates by blocking harmful cell activation and apoptosis through a specific cellular pathway.
- Creating nanoparticles that deliver MKP5 effectively reduced liver inflammation and fibrosis in mice, indicating that targeted therapy using MKP5 might be a new way to treat this condition.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!